Longeveron announced its Q3 2026 financial results, reporting a net loss of $6.1 million and $7.2 million in cash. The company is seeking a meeting with the FDA to discuss next steps following the ELPIS II Phase 2b trial for its HLHS treatment, which did not meet its primary endpoint but showed positive secondary outcomes. Longeveron is also reviewing strategic alternatives, including partnerships or a sale, to enhance shareholder value while implementing cost-saving measures. The company continues to develop its stem cell therapy for rare pediatric and aging-related diseases, with several FDA designations supporting its programs.
Longeveron's Q3 2026 financial results show a net loss of $6.1 million and $7.2 million in cash, providing context for readers. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US health stocks, 23 rose and 124 fell. Notable movers include NVAX at USD 8.75 with a 1-day change of -12.32% and a typical hold time of 60 days with 99% buy orders; SANA at USD 2.02 down 11.79%, hold time 26 days, with 60% buy orders; and CTXR at USD 0.53 up 11.19%, hold time 19 days, with 84% sell orders.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
